Sign in to view content

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD

David A. Eichenbaum, MD, FASRS

Video
Published 2019

Related

The Cilioretinal Artery is Protective Against Choroidal Neovascularization in Age-Related Macular Degeneration
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2018
APEX: A Phase II Randomized Clinical Trial Evaluating the Safety andPreliminary Efficacy of X-82 Administered Orally in the Treatment of Exudative AMD
Michael N. Cohen, MD
Updates from the Field
2020
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more